CLINICAL LABS & IMMUNODIAGNOSTICS

Cardiac Assay Menu

When seconds count, our assays provide reliable short-term and long-term risk information for patients with acute coronary syndrome. This helps your lab make a vital contribution to patient outcomes when it’s most needed.

Helping your lab support patients with the most urgent needs quickly

Patients presenting with chest pain and shortness of breath are time-critical emergencies that leave your lab no room for error or delay. Achieving the best patient outcomes requires the fastest intervention possible.

VITROS^® Cardiac Assays offer exceptional assay performance to help provide vital information to inform treatment decisions.

Helping your lab support patients with the most urgent needs quickly

VITROS Cardiac Assays offer exceptional assay performance to help provide vital information to inform treatment decisions.

Cardiac Assay Menu

VITROS® Menu of Assays by Disease State (PDF)

Apolipoprotein A1

Cholesterol

CK-MB

CKMB

D-Dimer*

Direct HDL

Direct LDL

Homocysteine

hsTroponin (D)

LDHi

Lp(a)*

Myoglobin

NT-proBNP

Triglycerides

Troponin I ES

The VITROS^® System

VITROS^® 7600 Integrated System
VITROS^® 5600 Integrated System
VITROS^® 3600 Immunodiagnostic System
VITROS^® ECI/ECiQ Immunodiagnostic System
VITROS^® 4600 Integrated System
VITROS^® XT 3400 Integrated System

*MicroTip Partnership Assay (MPA); Reagents and validated applications available directly from Ortho Clinical Diagnostics
D = In development/currently not available
§ For Criminal Justice and Forensic use only

For US:
VITROS^® Troponin I ES Assay

Improved assay sensitivity and precision delivers reliable short-term and long-term risk information for patients with acute coronary syndrome and supports single sample testing with serum/plasma equivalence.

Performance competitive with a currently available 5th Generation high sensitivity Troponin assays.
Guideline acceptable precision. Meets ACC/ESC guidelines for acceptable imprecision in a high sensitivity assay ( 10% coefficient of variation at the 99th percentile).
Validated clinical performance at the 99th percentile upper reference limit of normal enables accelerated rule-in/rule-out algorithms
Analyzer automated sample indices help ensure that actionable results are reported.
False positive Troponin T results have been reported in patients with kidney disease.¹ Troponin I biomarker elevations are more specific for myocardial damage than TroponinT elevations.²

For ex-US:
VITROS^® High-Sensitivity Troponin Assay^*

Provides high analytical sensitivity and precision for the detection of small changes at the 99th percentile, enabling early diagnosis of acute myocardial infarction
Features a high negative predictive value that helps reduce emergency department crowding and requires fewer tests to diagnose
Meets the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) classification as a high-sensitivity troponin assay
Shows excellent prognostic value as an aid in the assessment of cardiac-related mortality/MI and all-cause mortality over 30 days and 12 months
HS Troponin assay is compliant for use with guidelines for management of acute coronary syndrome, including ESC, AHA and NICE

For ex-US:
VITROS^® NT-proBNP II Assay

NT-proBNP is more stable than BNP, which is important when samples must be transported¹
NT-proBNP allows for better management of patients on common heart failure therapy (Entresto^®) compared to BNP ²
Most NT-proBNP assays correlate well to each other. (Not all BNP assays correlate well with other BNP assays.)³
The VITROS^® NT-proBNP II assay is validated with the state-of-the-art ICON cutoffs, which offer improved specificity as they account for age and renal function^4-8
The VITROS^® NT-proBNP II assay also incorporates our state-of-the-art MicroWell technology that features an analyte-specific coating designed to eliminate biotin interference

Comprehensive Care

Service & Support

Imagine going from clutter to clarity and having seamless control of your lab. Our Ortho Care^® Services and Informatics gives you the freedom to focus on patient care.

See how we support you

Informatics Solutions

Is it time to change the way you see your lab? Simplify data to unburden you from the disruptions, complexities and distractions that pull your focus away from patient care. See how network insights, open connectivity and quality management can drive the change your lab needs.

Explore informatics

_{¹Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med. 2004;42(8):942-944. doi:10.1515/CCLM.2004.153}

_{²Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54-61. doi:10.1161/CIRCULATIONAHA.114.013748}

_{³Collin-Chavagnac D, Dehoux M, Schellenberg F, Cauliez B, Maupas-Schwalm F, Lefevre G; Société Française de Biologie Clinique Cardiac Markers Working Group. Head-to-head comparison of 10 natriuretic peptide assays. Clin Chem Lab Med. 2015;53(11):1825-1837. doi:10.1515/cclm-2014-0592}

_{⁴Kim HN, Januzzi JL Jr. Natriuretic peptide testing in heart failure. Circulation. 2011;123(18):2015-2019. doi:10.1161/CIRCULATIONAHA.110.979500}

_{⁵Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006; Aug;52(8):1528-1538. doi:10.1373/clinchem.2006.069575}

_{⁶Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948-954. doi:10.1016/j.amjcard.2004.12.032}

_{⁷Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. Eur Heart J. 2006;27(3):330-337. doi:10.1093/eurheartj/ehi631}

_{⁸Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2(6):663-670. doi:10.1016/j.jchf.2014.09.001}

VITROS® Testing Menu

VITROS® Systems

Laboratory Management & Workflow

Ortho Care® Ops

Ortho Care® Intel

Ortho Care® Teams

Technical Documentation Library

Cardiac Assay Menu

When seconds count, our assays provide reliable short-term and long-term risk information for patients with acute coronary syndrome. This helps your lab make a vital contribution to patient outcomes when it’s most needed.

When seconds count, our assays provide reliable short-term and long-term risk information for patients with acute coronary syndrome. This helps your lab make a vital contribution to patient outcomes when it’s most needed.

Helping your lab support patients with the most urgent needs quickly

Helping your lab support patients with the most urgent needs quickly